GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 11:35:26 2024-06-28 am EDT 5-day change 1st Jan Change
1,530 GBX +0.23% Intraday chart for GSK plc -4.35% +5.47%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GSK reaches settlement over Zantac case in Illinois AN
GSK Reaches Settlement in Illinois Zantac Lawsuit DJ
GSK Reaches Confidential Settlement in Illinois Zantac Litigation MT
GSK Reaches Confidential Settlement in Illinois Zantac Litigation MT
Sembcorp Inks Power Deals with GSK for Singapore Manufacturing Sites; Shares Down 3% MT
Health Care Stocks Fall With Broad Market -- Health Care Roundup DJ
London's FTSE 100 slips as investors eye US, UK economic data RE
GSK shares fall, penalized by CDC guidelines CF
GSK Shares Slump After CDC Narrows Age Recommendation for RSV Shots DJ
CDC Updates RSV Shot Recommendation Among the Elderly; Vaccine Makers Mixed Pre-Bell MT
Tepid trade as eyes on elections, US inflation AN
GSK : JP Morgan keeps a Sell rating ZD
European Midday Briefing: Skittish Mood Ahead of French Elections; U.S. Data Eyed DJ
GSK: ACIP recommends RSV vaccine for the over 75s CF
Nervy trade in London before US data AN
London stocks subdued as investors digest corporate updates; eye on economic data RE
GSK slides 6% after US CDC narrows scope of RSV shots RE
GSK : Receives a Buy rating from UBS ZD
Moderna Shares Fall as RSV Shot Efficacy Lags Behind Rivals' Vaccines, CDC Data Shows MT
CDC advisers narrow age recommendation for RSV shots in US RE
US CDC Advisers Recommend RSV Vaccine For Adults Aged 60 Years Of Age And Above RE
Moderna RSV Shot Efficacy Lower Than Rivals' Vaccines, CDC Data Shows MT
Moderna RSV Shot Efficacy Lower Than Rivals', CDC Data Shows; Shares Down 9.5% MT
Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer CI
European Equities Close Higher on Monday; EU Probes Apple for Breach of Digital Competition Law MT
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.26 GBP
Average target price
20.28 GBP
Spread / Average Target
+32.93%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. AlphaValue/Baader Europe Upgrades GSK to Buy from Add, Lifts PT